Therefore, inhibition of MAPK14 may be a valuable drug target for the treatment of COPD, and such inhibition for the treatment of ARDS, which involves the same pathological state of the respiratory system, also warrants study [45]. This evidence concerns the gene MAPK14 and chronic obstructive pulmonary disease.